The Emerging Role of EVA1A in Different Types of Cancers
Abstract
:1. Introduction
2. The Role of EVA1A in Breast Cancer
3. The Role of EVA1A in Papillary Thyroid Cancer
4. The Role of EVA1A in Non-Small Cell Lung Cancer Cells
5. The Role of EVA1A in Hepatocellular Carcinoma
6. The Role of EVA1A in Glioblastoma
7. The Role of EVA1A in Pancreatic Cancer
8. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Hu, J.; Li, G.; Qu, L.J.; Li, N.; Liu, W.; Xia, D.; Hongdu, B.Q.; Lin, X.; Xu, C.; Lou, Y.; et al. TMEM166/EVA1A interacts with ATG16L1 and induces autophagosome formation and cell death. Cell Death Dis. 2016, 7, e2323. [Google Scholar] [CrossRef] [PubMed]
- Wang, L.; Yu, C.; Lu, Y.; He, P.; Guo, J.; Zhang, C.; Song, Q.; Ma, D.; Shi, T.; Chen, Y. TMEM166, a novel transmembrane protein, regulates cell autophagy and apoptosis. Apoptosis 2007, 12, 1489–1502. [Google Scholar] [CrossRef] [PubMed]
- Zhang, S.; Lin, X.; Li, G.; Shen, X.; Niu, D.; Lu, G.; Fu, X.; Chen, Y.; Cui, M.; Bai, Y. Knockout of Eva1a leads to rapid development of heart failure by impairing autophagy. Cell Death Dis. 2017, 8, e2586. [Google Scholar] [CrossRef] [PubMed]
- Xu, D.; Yang, F.; He, H.; Hu, J.; Lv, X.; Ma, D.; Chen, Y.Y. Expression of TMEM166 Protein in Human Normal and Tumor Tissues. Appl. Immunohistochem. Mol. Morphol. 2013, 21, 543–552. [Google Scholar] [CrossRef]
- Sun, W.; Ma, X.-M.; Bai, J.-P.; Zhang, G.-Q.; Zhu, Y.-J.; Ma, H.-M.; Guo, H.; Chen, Y.-Y.; Ding, J.-B. Transmembrane protein 166 expression in esophageal squamous cell carcinoma in Xinjiang, China. Asian Pac. J. Cancer Prev. 2012, 13, 3713–3716. [Google Scholar] [CrossRef] [Green Version]
- Tao, M.; Shi, X.-Y.; Yuan, C.-H.; Hu, J.; Ma, Z.-L.; Jiang, B.; Xiu, D.-R.; Chen, Y.-Y. Expression Profile and Potential Roles of EVA1A in Normal and Neoplastic Pancreatic Tissues. Asian Pac. J. Cancer Prev. 2015, 16, 373–376. [Google Scholar] [CrossRef] [Green Version]
- Chang, Y.; Li, Y.; Hu, J.; Guo, J.; Xu, D.; Xie, H.; Lv, X.; Shi, T.; Chen, Y. Adenovirus vector-mediated expression of TMEM166 inhibits human cancer cell growth by autophagy and apoptosis in vitro and in vivo. Cancer Lett. 2012, 328, 126–134. [Google Scholar] [CrossRef]
- Lu, G.; Ang, Y.H.; Zhou, J.; Tamilarasi, J.; Yan, B.; Lim, Y.C.; Srivastava, S.; Salto-Tellez, M.; Hui, K.M.; Shen, H.; et al. CCAAT/enhancer binding protein α predicts poorer prognosis and prevents energy starvation–induced cell death in hepatocellular carcinoma. Hepatology 2014, 61, 965–978. [Google Scholar] [CrossRef]
- Li, M.; Lu, G.; Hu, J.; Shen, X.; Ju, J.; Gao, Y.; Qu, L.; Xia, Y.; Chen, Y.; Bai, Y. EVA1A/TMEM166 Regulates Embryonic Neurogenesis by Autophagy. Stem Cell Rep. 2016, 6, 396–410. [Google Scholar] [CrossRef] [Green Version]
- Lin, X.; Cui, M.; Xu, D.; Hong, D.; Xia, Y.; Xu, C.; Li, R.; Zhang, X.; Lou, Y.; He, Q.; et al. Liver-specific deletion of Eva1a/Tmem166 aggravates acute liver injury by impairing autophagy. Cell Death Dis. 2018, 9, 768. [Google Scholar] [CrossRef] [Green Version]
- Zhen, Y.; Zhao, R.; Wang, M.; Jiang, X.; Gao, F.; Fu, L.; Zhang, L.; Zhou, X.-L. Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer. Theranostics 2020, 10, 8080–8097. [Google Scholar] [CrossRef]
- Liu, H.; Li, F.; Zhang, X.; Yu, J.; Wang, J.; Jia, J.; Yu, X.; Shen, Z.; Yuan, Z.; Zhang, X.; et al. Differentially Expressed Intrahepatic Genes Contribute to Control of Hepatitis B Virus Replication in the Inactive Carrier Phase. J. Infect. Dis. 2018, 217, 1044–1054. [Google Scholar] [CrossRef]
- Zhao, S.; Wang, H. EVA1A Plays an Important Role by Regulating Autophagy in Physiological and Pathological Processes. Int. J. Mol. Sci. 2021, 22, 6181. [Google Scholar] [CrossRef]
- Pearce, L. Breast cancer. Nurs. Stand. 2016, 30, 15. [Google Scholar] [CrossRef]
- Wolff, A.C.; Hammond, M.E.; Hicks, D.G.; Dowsett, M.; McShane, L.M.; Allison, K.H.; Allred, D.C.; Bartlett, J.M.; Bilous, M.; Fitzgibbons, P.; et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 2013, 31, 3997–4013. [Google Scholar] [CrossRef]
- Kumar, P.; Aggarwal, R. An overview of triple-negative breast cancer. Arch. Gynecol. Obstet. 2015, 293, 247–269. [Google Scholar] [CrossRef]
- Kwapisz, D. Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol. Immunother. 2020, 70, 607–617. [Google Scholar] [CrossRef]
- Lyons, T.G. Targeted Therapies for Triple-Negative Breast Cancer. Curr. Treat. Options Oncol. 2019, 20, 82. [Google Scholar] [CrossRef]
- Hwang, S.-Y.; Park, S.; Kwon, Y. Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol. Ther. 2019, 199, 30–57. [Google Scholar] [CrossRef]
- Chang-Qing, Y.; Jie, L.; Shi-Qi, Z.; Kun, Z.; Zi-Qian, G.; Ran, X.; Hui-Meng, L.; Ren-Bin, Z.; Gang, Z.; Da-Chuan, Y.; et al. Recent treatment progress of triple negative breast cancer. Prog. Biophys. Mol. Biol. 2019, 151, 40–53. [Google Scholar] [CrossRef]
- Zhou, X.; Zou, L.; Chen, W.; Yang, T.; Luo, J.; Wu, K.; Shu, F.; Tan, X.; Yang, Y.; Cen, S.; et al. Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer. Pharmacol. Res. 2020, 164, 105305. [Google Scholar] [CrossRef]
- Zhang, L.; Guo, M.; Li, J.; Zheng, Y.; Zhang, S.; Xie, T.; Liu, B. Systems biology-based discovery of a potential Atg4B agonist (Flubendazole) that induces autophagy in breast cancer. Mol. BioSyst. 2015, 11, 2860–2866. [Google Scholar] [CrossRef]
- Schwartz, L.M. Autophagic Cell Death during Development—Ancient and Mysterious. Front. Cell Dev. Biol. 2021, 9, 813. [Google Scholar] [CrossRef]
- Ali, R.; Islamuddin, M.; Tabrez, S.; Alsaweed, M.; Alaidarous, M.A.; Alshehri, B.M.; Banawas, S.; Bin Dukhyil, A.A.; Rub, A. Embilica officinalis L. inhibits the growth and proliferation of Leishmania donovani through the induction of ultrastructural changes, mitochondrial dysfunction, oxidative stress and apoptosis-like cell death. Biomed. Pharmacother. 2021, 143, 112156. [Google Scholar] [CrossRef]
- Wandee, J.; Srinontong, P.; Prawan, A.; Senggunprai, L.; Kongpetch, S.; Yenjai, C.; Kukongviriyapan, V. Derrischalcone suppresses cholangiocarcinoma cells through targeting ROS-mediated mitochondrial cell death, Akt/mTOR, and FAK pathways. Naunyn Schmiedebergs Arch. Pharmacol. 2021, 394, 1929–1940. [Google Scholar] [CrossRef]
- Bock, F.J.; Tait, S.W.G. Mitochondria as multifaceted regulators of cell death. Nat. Rev. Mol. Cell Biol. 2019, 21, 85–100. [Google Scholar] [CrossRef]
- Bhatti, J.S.; Bhatti, G.K.; Reddy, P.H. Mitochondrial dysfunction and oxidative stress in metabolic disorders—A step towards mitochondria based therapeutic strategies. Biochim. Biophys. Acta Mol. Basis Dis. 2017, 1863, 1066–1077. [Google Scholar] [CrossRef]
- Zhen, Y.; Yuan, Z.; Zhang, J.; Chen, Y.; Fu, Y.; Liu, Y.; Fu, L.; Zhang, L.; Zhou, X.-L. Flubendazole induces mitochondrial dysfunction and DRP1-mediated mitophagy by targeting EVA1A in breast cancer. Cell Death Dis. 2022, 13, 375. [Google Scholar] [CrossRef]
- Lu, H.; Li, G.; Liu, L.; Feng, L.; Wang, X.; Jin, H. Regulation and function of mitophagy in development and cancer. Autophagy 2013, 9, 1720–1736. [Google Scholar] [CrossRef]
- Xu, H.-M.; Hu, F. The role of autophagy and mitophagy in cancers. Arch. Physiol. Biochem. 2022, 128, 281–289. [Google Scholar] [CrossRef]
- Vasileiadis, I.; Boutzios, G.; Karalaki, M.; Misiakos, E.; Karatzas, T. Papillary thyroid carcinoma of the isthmus: Total thyroidectomy or isthmusectomy? Am. J. Surg. 2018, 216, 135–139. [Google Scholar] [CrossRef] [PubMed]
- Driouich, Y.; Haraj, N.E.; El Aziz, S.; Chadli, A. Impact of pregnancy on papillary thyroid carcinoma prognosis. Pan Afr. Med. J. 2021, 38, 261. [Google Scholar] [CrossRef] [PubMed]
- Baerbock, N.; Mittelstädt, A.; Jähne, J. Morbidity and long-term survival in patients with cervical re-exploration for papillary thyroid carcinoma. Innov. Surg. Sci. 2019, 4, 91–99. [Google Scholar] [CrossRef] [PubMed]
- Nixon, I.J.; Shaha, A.R. Recurrent differentiated thyroid cancer. Endocr. Pract. 2012, 18, 600–603. [Google Scholar]
- Dong, S.; Xue, S.; Sun, Y.; Han, Z.; Sun, L.; Xu, J.; Liu, J. MicroRNA-363-3p downregulation in papillary thyroid cancer inhibits tumor progression by targeting NOB. J. Investig. Med. 2020, 69, 66–74. [Google Scholar] [CrossRef]
- Lin, B.; Wen, J.; Zheng, C.; Lin, L.; Chen, C.; Qu, J. Eva-1 homolog A promotes papillary thyroid cancer progression and epithelial-mesenchymal transition via the Hippo signalling pathway. J. Cell. Mol. Med. 2020, 24, 13070–13080. [Google Scholar] [CrossRef]
- Suster, D.I.; Mino-Kenudson, M. Molecular Pathology of Primary Non-small Cell Lung Cancer. Arch. Med. Res. 2020, 51, 784–798. [Google Scholar] [CrossRef]
- Majem, B.; Nadal, E.; Muñoz-Pinedo, C. Exploiting metabolic vulnerabilities of Non small cell lung carcinoma. Semin. Cell Dev. Biol. 2019, 98, 54–62. [Google Scholar] [CrossRef]
- Remark, R.; Becker, C.; Gomez, J.; Damotte, D.; Dieu-Nosjean, M.-C.; Sautes-Fridman, C.; Fridman, W.H.; Powell, C.; Altorki, N.K.; Merad, M.; et al. The Non–Small Cell Lung Cancer Immune Contexture. A Major Determinant of Tumor Characteristics and Patient Outcome. Am. J. Respir. Crit. Care Med. 2015, 191, 377–390. [Google Scholar] [CrossRef] [Green Version]
- Nascimento, A.; Bousbaa, H.; Ferreira, D.; Sarmento, B. Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy. Curr. Drug Targets 2015, 16, 1448–1463. [Google Scholar] [CrossRef]
- Xie, H.; Hu, J.; Pan, H.; Lou, Y.; Lv, P.; Chen, Y. Adenovirus vector-mediated FAM176A overexpression induces cell death in human H1299 non-small cell lung cancer cells. BMB Rep. 2014, 47, 104–109. [Google Scholar] [CrossRef] [Green Version]
- Zhu, H.; Zhang, Y. Life and Death Partners in Post-PCI Restenosis: Apoptosis, Autophagy, and the Cross-talk Between Them. Curr. Drug Targets 2018, 19, 1003–1008. [Google Scholar] [CrossRef]
- El-Khoueiry, A.B.; Hanna, D.L.; Llovet, J.; Kelley, R.K. Cabozantinib: An evolving therapy for hepatocellular carcinoma. Cancer Treat. Rev. 2021, 98, 102221. [Google Scholar] [CrossRef]
- Juaid, N.; Amin, A.; Abdalla, A.; Reese, K.; Alamri, Z.; Moulay, M.; Abdu, S.; Miled, N. Anti-Hepatocellular Carcinoma Biomolecules: Molecular Targets Insights. Int. J. Mol. Sci. 2021, 22, 10774. [Google Scholar] [CrossRef]
- Sugawara, Y.; Hibi, T. Surgical treatment of hepatocellular carcinoma. Biosci. Trends 2021, 15, 138–141. [Google Scholar] [CrossRef]
- Budny, A.; Kozłowski, P.; Kamińska, M.; Jankiewicz, M.; Kolak, A.; Budny, B.; Budny, W.; Niemunis-Sawicka, J.; Szczypiór, G.; Kurniawka, B.; et al. Epidemiology and risk factors of hepatocellular carcinoma. Pol. Merkur. Lek. Organ Pol. Tow. Lek. 2017, 43, 133–139. [Google Scholar]
- Liu, Z.; Liu, X.; Liang, J.; Liu, Y.; Hou, X.; Zhang, M.; Li, Y.; Jiang, X. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects. Front. Immunol. 2021, 12, 4165. [Google Scholar] [CrossRef]
- Etık, D.O.; Suna, N.; Boyacioglu, A.S. Management of Hepatocellular Carcinoma: Prevention, Surveillance, Diagnosis, and Staging. Exp. Clin. Transplant. 2017, 15, 31–35. [Google Scholar] [CrossRef] [Green Version]
- Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281–297. [Google Scholar] [CrossRef] [Green Version]
- Peng, B.; Theng, P.Y.; Le, M.T.N. Essential functions of miR-125b in cancer. Cell Prolif. 2020, 54, e12913. [Google Scholar] [CrossRef]
- Yang, M.; Wei, S.; Zhao, H.; Zhou, D.; Cui, X. The role of miRNA125b in the progression of hepatocellular carcinoma. Clin. Res. Hepatol. Gastroenterol. 2021, 45, 101712. [Google Scholar] [CrossRef]
- Ren, W.W.; Li, D.D.; Chen, X.; Li, X.L.; He, Y.P.; Guo, L.H.; Liu, L.N.; Sun, L.P.; Zhang, X.P. MicroRNA-125b reverses oxaliplatin resistance in hepatocellular carcinoma by negatively regulating EVA1A mediated autophagy. Cell Death Dis. 2018, 9, 547. [Google Scholar] [CrossRef] [Green Version]
- Hu, F.; Song, D.; Yan, Y.; Huang, C.; Shen, C.; Lan, J.; Chen, Y.; Liu, A.; Wu, Q.; Sun, L.; et al. IL-6 regulates autophagy and chemotherapy resistance by promoting BECN1 phosphorylation. Nat. Commun. 2021, 12, 3651. [Google Scholar] [CrossRef]
- Xuan, Y.; Zhao, S.; Xiao, X.; Xiang, L.; Zheng, H.-C. Inhibition of chaperone-mediated autophagy reduces tumor growth and metastasis and promotes drug sensitivity in colorectal cancer. Mol. Med. Rep. 2021, 23, 360. [Google Scholar] [CrossRef]
- Yang, J.; Wang, B.; Xu, Q.; Yang, Y.; Hou, L.; Yin, K.; Guo, Q.; Hua, Y.; Zhang, L.; Li, Y.; et al. TMEM166 inhibits cell proliferation, migration and invasion in hepatocellular carcinoma via upregulating TP. Mol. Cell. Biochem. 2020, 476, 1151–1163. [Google Scholar] [CrossRef]
- Luo, Z.; Xu, X.; Sho, T.; Zhang, J.; Xu, W.; Yao, J.; Xu, J. ROS-induced autophagy regulates porcine trophectoderm cell apoptosis, proliferation, and differentiation. Am. J. Physiol. Physiol. 2019, 316, C198–C209. [Google Scholar] [CrossRef]
- Gui, D.; Cui, Z.; Zhang, L.; Yu, C.; Yao, D.; Xu, M.; Chen, M.; Wu, P.; Li, G.; Wang, L.; et al. Salidroside attenuates hypoxia-induced pulmonary arterial smooth muscle cell proliferation and apoptosis resistance by upregulating autophagy through the AMPK-mTOR-ULK1 pathway. BMC Pulm. Med. 2017, 17, 191. [Google Scholar] [CrossRef] [Green Version]
- Song, P.; Li, Y.; Dong, Y.; Liang, Y.; Qu, H.; Qi, D.; Lu, Y.; Jin, X.; Guo, Y.; Jia, Y.; et al. Estrogen receptor beta inhibits breast cancer cells migration and invasion through CLDN6-mediated autophagy. J. Exp. Clin. Cancer Res. 2019, 38, 354. [Google Scholar] [CrossRef] [Green Version]
- Li, L.; Peng, W.; Zhou, Q.; Wan, J.P.; Wang, X.T.; Qi, H.B. LRP6 regulates Rab7-mediated autophagy through the Wnt/beta-catenin pathway to modulate trophoblast cell migration and invasion. J. Cell Biochem. 2020, 121, 1599–1609. [Google Scholar] [CrossRef]
- Ma, R.; Taphoorn, M.J.B.; Plaha, P. Advances in the management of glioblastoma. J. Neurol. Neurosurg. Psychiatry 2021, 92, 1103–1111. [Google Scholar] [CrossRef]
- Tamimi, A.F.; Juweid, M. Epidemiology and Outcome of Glioblastoma. In Glioblastoma; De Vleeschouwer, S., Ed.; Exon Publications: Brisbane, Australia, 2017. [Google Scholar]
- Koshy, M.; Villano, J.L.; Dolecek, T.A.; Howard, A.; Mahmood, U.; Chmura, S.J.; Weichselbaum, R.R.; McCarthy, B.J. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J. Neurooncol. 2012, 107, 207–212. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Carballo, G.B.; Ribeiro, J.H.; Lopes, G.P.D.F.; Ferrer, V.P.; Dezonne, R.S.; Pereira, C.; Spohr, T.C.L.D.S.E. GANT-61 Induces Autophagy and Apoptosis in Glioblastoma Cells despite their heterogeneity. Cell. Mol. Neurobiol. 2020, 41, 1227–1244. [Google Scholar] [CrossRef] [PubMed]
- Yang, H.-L.; Tsai, C.-H.; Shrestha, S.; Lee, C.-C.; Liao, J.-W.; Hseu, Y.-C. Coenzyme Q0, a novel quinone derivative of Antrodia camphorata, induces ROS-mediated cytotoxic autophagy and apoptosis against human glioblastoma cells in vitro and in vivo. Food Chem. Toxicol. 2021, 155, 112384. [Google Scholar] [CrossRef] [PubMed]
- Urdiciain, A.; Erausquin, E.; Zelaya, M.; Zazpe, I.; Lanciego, J.; Meléndez, B.; Rey, J.; Idoate, M.; Galdo, N.R.-D.; Castresana, J. Silencing of Histone Deacetylase 6 Decreases Cellular Malignancy and Contributes to Primary Cilium Restoration, Epithelial-to-Mesenchymal Transition Reversion, and Autophagy Inhibition in Glioblastoma Cell Lines. Biology 2021, 10, 467. [Google Scholar] [CrossRef]
- Shen, X.; Kan, S.; Liu, Z.; Lu, G.; Zhang, X.; Chen, Y.; Bai, Y. EVA1A inhibits GBM cell proliferation by inducing autophagy and apoptosis. Exp. Cell Res. 2017, 352, 130–138. [Google Scholar] [CrossRef]
- Wang, J.; Qi, Q.; Zhou, W.; Feng, Z.; Huang, B.; Chen, A.; Zhang, D.; Li, W.; Zhang, Q.; Jiang, Z.; et al. Inhibition of glioma growth by flavokawain B is mediated through endoplasmic reticulum stress induced autophagy. Autophagy 2018, 14, 2007–2022. [Google Scholar] [CrossRef] [Green Version]
- Wang, D.; He, J.; Dong, J.; Wu, S.; Liu, S.; Zhu, H.; Xu, T. UM-6 induces autophagy and apoptosis via the Hippo-YAP signaling pathway in cervical cancer. Cancer Lett. 2021, 519, 2–19. [Google Scholar] [CrossRef]
- Wang, H.; Zhong, P.; Sun, L. Exogenous hydrogen sulfide mitigates NLRP3 inflammasome-mediated inflammation through promoting autophagy via the AMPK-mTOR pathway. Biol. Open 2019, 8, bio043653. [Google Scholar] [CrossRef] [Green Version]
- Rosen, M.N.; A Goodwin, R.; Vickers, M.M. BRCA mutated pancreatic cancer: A change is coming. World J. Gastroenterol. 2021, 27, 1943–1958. [Google Scholar] [CrossRef]
- Tonini, V.; Zanni, M. Pancreatic cancer in 2021: What you need to know to win. World J. Gastroenterol. 2021, 27, 5851–5889. [Google Scholar] [CrossRef]
- Biller, L.H.; Wolpin, B.M.; Goggins, M. Inherited Pancreatic Cancer Syndromes and High-Risk Screening. Surg. Oncol. Clin. N. Am. 2021, 30, 773–786. [Google Scholar] [CrossRef]
- Kearney, J.F.; Adsay, V.; Yeh, J.J. Pathology and Molecular Characteristics of Pancreatic Cancer. Surg. Oncol. Clin. N. Am. 2021, 30, 609–619. [Google Scholar] [CrossRef]
- Wang, Z.; Han, S.; Chen, X.; Li, X.; Xia, N.; Pu, L. Eva1a inhibits NLRP3 activation to reduce liver ischemia-reperfusion injury via inducing autophagy in kupffer cells. Mol. Immunol. 2021, 132, 82–92. [Google Scholar] [CrossRef]
- Wu, D.; Zhong, P.; Wang, J.; Wang, H. Exogenous hydrogen sulfide mitigates LPS + ATP-induced inflammation by inhibiting NLRP3 inflammasome activation and promoting autophagy in L02 cells. Mol. Cell. Biochem. 2019, 457, 145–156. [Google Scholar] [CrossRef]
The Type of Cancer | The Role and Mechanism of EVA1A in Cancer | Experimental Model | Reference |
---|---|---|---|
triple-negative breast cancer (TNBC) | EVA1A improves TNBC through promotion of autophagic death of TNBC cells via ATG5 | TNBC cells and xenograft mouse models | [11] |
breast cancer | flubendazole suppressed breast cancer through induction of mitochondrial dysfunction by promoting DRP1-mediated mitophagy via upregulating EVA1A | MDA-MB-231 and MCF-7 cells | [28] |
papillary thyroid carcinoma (PTC) | EVA1A promotes PTC progression through the activation of Hippo pathway | the tumor tissue of the patients with PTC and PTC cells | [36] |
non-small cell lung cancer | EVA1A inhibits NSCLC through promotion of apoptosis, autophagy and cell cycle arrest | lung cancer cell lines H1299 cells | [41] |
hepatocellular carcinoma (HCC) | EVA1A enhances oxaliplatin resistance of HCC through induction of autophagy | the tumor tissue from oxaliplatin-resistant HCC patients and HCC cells | [52] |
HCC | EVA1 inhibits HCC through inhibition of cell proliferation, migration and invasion via increasing TP53 | the tumor tissue from oxaliplatin-resistant HCC patients and HCC cells | [55] |
Glioblastoma (GBM) | EVA1A suppresses GBM cell proliferation through promotion of autophagy by inhibiting mTOR/RPS6KB1 pathway | GBM cells | [61] |
Pancreatic cancer | the ectopic expression of EVA1A in pancreas promotes the occurrence and development of pancreatic cancer | human normal and neoplastic pancreatic tissues | [6] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zhao, H.; Liu, H.; Yang, Y.; Wang, H. The Emerging Role of EVA1A in Different Types of Cancers. Int. J. Mol. Sci. 2022, 23, 6665. https://doi.org/10.3390/ijms23126665
Zhao H, Liu H, Yang Y, Wang H. The Emerging Role of EVA1A in Different Types of Cancers. International Journal of Molecular Sciences. 2022; 23(12):6665. https://doi.org/10.3390/ijms23126665
Chicago/Turabian StyleZhao, Huijie, Huiyang Liu, Yihan Yang, and Honggang Wang. 2022. "The Emerging Role of EVA1A in Different Types of Cancers" International Journal of Molecular Sciences 23, no. 12: 6665. https://doi.org/10.3390/ijms23126665